5. Summary and Conclusion

Total Page:16

File Type:pdf, Size:1020Kb

5. Summary and Conclusion 5.1 Summary 215 5. Summary and Conclusion 5.1. Summary Nanoparticles are being developed for a multitude of applications in the fields of biomed- icine and reproductive biology to date. An appealing fabrication method is the pulsed la- ser ablation in liquids (PLAL), which enables the production of gold nanoparticles and also their in situ bioconjugation with biomolecules on the timescale of minutes. A crucial drawback of the PLAL process is generally that there is a mis- match between an efficient production yield and the maintenance of optimal conditions for the fabrication of functional nanobioconjugates. For a long time, only a maximum nanobioconjugate yield of approxi- mately 11 µg min-1 had been achieved using femtosecond-pulsed LAL that resulted in nearly 100 % integrity preservation of biomolecules.[39] That was the basis for the development of this thesis. To enhance the nanoparticle yield, it was studied whether longer pulse duration could increase the ablated gold mass per time. In fact, us- ing picosecond pulses for PLAL instead of femtosecond pulses, the nanobioconjugate yield was significantly increased by a factor of 15 to 168 µg min-1. Moreover, the pro- duced nanobioconjugates featured nearly 100 % integrity preservation when fabricated with strictly defined process parameters. Interestingly, the nanoparticle concentration could be further increased by the post-processing techniques of ultrafiltration and solvent evaporation. A maximum concentration factor of 2-3 was reached with ultrafiltration. The up-concentrated nanobioconjugates were functional; however the efficiency of ultrafiltra- tion was highly dependent on the material of the filter membrane. Moreover, high particle losses of approximately 40 % had to be accepted. Conversely, the concentration increase of nanobiohybrids by solvent evaporation was highly efficient by a factor of 13. However, because of long processing times at room temperature the risk of biomolecule inactiva- tion is quite high and should be considered carefully. In summary, the adoption of ps-PLAL for AuNP and AuNP bioconjugate fabrication could allow for competitiveness of the PLAL technique on the NP fabrication market, especially if it is combined with an additional post-processing step of ultrafiltration or solvent evaporation, yielding mg mL-1 concentration scale. When starting the work on this thesis, there had been no comprehensive guideline for the laser-based fabrication of gold nanoparticle bioconju- gates, especially regarding the specific demand on structure-function relationship. During the thesis workout, it turned out to be a particular challenge to include all relevant process parameters because of their di- versity. Moreover, the parameters did not only influence the conjugation process but they © Springer Fachmedien Wiesbaden 2016 A. Barchanski, Laser-Generated Functional Nanoparticle Bioconjugates, DOI 10.1007/978-3-658-13515-7 216 5 Summary and Conclusion could also amplify or erase the benefit and function of each other. However, four consid- eration areas were subdivided for the discussion of the process parameters. (I) The effects of nanoparticles’ intrinsic parameters were studied on the examples of particle size and surface charge. The methods of in situ photofragmentation and ex situ centrifugation were successfully applied to modify the particle size distribution and to separate distinct particle size classes. Moreover, the fabrication of AuNPs with ps-PLAL was found to generate partially oxidized surfaces (~ 5 % of atoms) with an Au+ configuration. Compared to other studies, the extent of surface oxidation seems to be strongly dependent on the laser parameters such as pulse length, pulse energy, repetition rate, fluence and wavelength. (II) Choice of binding stability and functional group, of ligand amount and ligand charge and of the surrounding medium. The solvent for ablation should provide optimal conditions for the electro- static stability of nanoparticles and biomolecules and it should allow for the dilution or transfer of nanobioconjugates into biological relevant media. For optimal binding stability, the covalent attachment of ligands with a thiol or disulfide function should be aimed. There was no difference for the conjugation by thiol or disul- fide function determined. However, the molecule structure should be considered careful- ly, because spontaneous fragmentation/dissolution of AuNPs by electron transfer from electron-donor-containing moieties could occur. To achieve optimal nanobioconjugate formation and functionality without precipitation or multilayer formation, the adopted ligand concentration should be within a concentration window that is defined by two thresholds termed minimum ligand concentration and maximum ligand concentration. The effect of charge compensation between net-charge negative AuNPs and net-charge positive ligands should be avoided, because it induces the reduction of the interparticle distance and allows for particle agglomeration. (III) Ligand characteristics as their length, dimension, binding orientation or amphiphilic nature and the adoption of diverse ligands for bivalent functionalization and surface saturation. The chain of linear ligands should be kept short to avoid enhanced coiling and wrapping effects of the flexible ligands around the AuNP surface, which significantly limits the surface coverage. Moreover, it should be considered that the molecular size is in direct relation to a large molecular footprint and thus to the number of attachable ligands. For ligands that have active centers, a correct orientation on the nanoparticles should be ena- bled by the use of specific linker molecules. In addition, it should be considered for nu- cleotides that the insertion position of a sulphuric function at the strand end will either yield a high amount of full-length and capped failure nucleotides with the modification or 5.1 Summary 217 only a low amount of the full-length product with the modification. The fabrication of bivalent AuNP bioconjugates can be enabled with three different approaches, including the in situ conjugation with ligand A and the ex situ conjugation with ligand B, the in situ conjugation with ligand B and the ex situ conjugation with ligand A and the in situ co-conjugation with both ligands at once. All approaches will result in bivalent conjugates. However, the co-conjugation is most effective due to a single-step process. A non-functional dummy ligand might be applied to pre-saturate the particle surface in order to control the surface coverage of a functional secondary ligand. However, it may also be applied to post-saturate the particle in order to increase the nanobioconjugate sta- bility even in highly saline media. Moreover, the amphiphilic nature of the biomolecule may influence the biological functionality of the nanobioconjugates. Depending on the application, polycationic, bivalent bioconjugates should feature different properties than cationic-neutral, bivalent bioconjugates and amphiphilic bioconjugates with a twisted ani- onic-neutral-cationic composition and a high hydrophobic content. (IV) The biological functionality of nanobioconjugates is their most crucial quality. Thus, the PLAL-generated conjugates that were fabricated in the framework of this thesis were analyzed regarding functionality in various laboratory assays such as immunoblotting and they were applied for in vitro tests such as cellular uptake studies, cytotoxicity screening or the specific immunolabeling. Within all those studies, the PLAL-generated nanobioconjugates were highly functional and featured the same or even a better quality than commercial products. The transferability of an established technique e.g. from one to another materials is an important factor for the broadband-compatibility of a method. When the structure of this thesis was outlined, the laser-based in situ bioconjugation was solely used for the functionalization of gold nanoparticles with (thiolized) ligands in a single-step process. However, the adoption of the technique to other biologically relevant materials such as silicon and iron was of high interest. Within this thesis, the fabrication of silicon nanobioconjugates and magnetic, iron-based nanobioconjugates with in situ bioconjugation technique during PLAL was successfully demonstrated. The obtained nanobioconjugates were directly fab- ricated in ultrapure water and featured a high colloidal stability. This is outstanding, com- pared to the conventional biofunctionalization approaches of nanoparticles from those materials, which are generally performed in organic solvents with high amounts of stabi- lizers and which comprise complex purification procedures. However, with in situ biocon- jugation method, reasonable surface coverage values were gained, depending on the con- jugation mechanism and applied biomolecule. Moreover, the nanobioconjugates featured biological functionality for bio-imaging and magnetic manipulation applications and are highly promising for biomedical applications. 218 5 Summary and Conclusion 5.2. Conclusion and Outlook Golden bioperspective Thus far, the nanotechnology has transcended the traditional boundaries between com- mon research areas such as physics, chemistry and biology/medicine and has been charac- terized by its capacity to revolutionize nearly everything. This has made the work on this thesis highly challenging but also very exciting. This thesis deals with the complex issue of functional nanobioconjugate fabrication with in situ
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin Et Al
    USOO91 01662B2 (12) United States Patent (10) Patent No.: US 9,101,662 B2 Tamarkin et al. (45) Date of Patent: *Aug. 11, 2015 (54) COMPOSITIONS WITH MODULATING A61K 47/32 (2013.01); A61 K9/0014 (2013.01); AGENTS A61 K9/0031 (2013.01); A61 K9/0034 (2013.01); A61 K9/0043 (2013.01); A61 K (71) Applicant: Foamix Pharmaceuticals Ltd., Rehovot 9/0046 (2013.01); A61 K9/0048 (2013.01); (IL) A61 K9/0056 (2013.01) (72) Inventors: Dov Tamarkin, Macabim (IL); Meir (58) Field of Classification Search Eini, Ness Ziona (IL); Doron Friedman, CPC ........................................................ A61 K9/12 Karmei Yosef (IL); Tal Berman, Rishon See application file for complete search history. le Ziyyon (IL); David Schuz, Gimzu (IL) (56) References Cited (73) Assignee: Foamix Pharmaceuticals Ltd., Rehovot U.S. PATENT DOCUMENTS (IL) 1,159,250 A 11/1915 Moulton (*) Notice: Subject to any disclaimer, the term of this 1,666,684 A 4, 1928 Carstens patent is extended or adjusted under 35 1924,972 A 8, 1933 Beckert 2,085,733. A T. 1937 Bird U.S.C. 154(b) by 0 days. 2,390,921 A 12, 1945 Clark This patent is Subject to a terminal dis 2,524,590 A 10, 1950 Boe claimer. 2,586.287 A 2/1952 Apperson 2,617,754 A 1 1/1952 Neely 2,767,712 A 10, 1956 Waterman (21) Appl. No.: 14/045,528 2.968,628 A 1/1961 Reed 3,004,894 A 10/1961 Johnson et al. (22) Filed: Oct. 3, 2013 3,062,715 A 11/1962 Reese et al.
    [Show full text]
  • Dissociation Constants of Organic Acids and Bases
    DISSOCIATION CONSTANTS OF ORGANIC ACIDS AND BASES This table lists the dissociation (ionization) constants of over pKa + pKb = pKwater = 14.00 (at 25°C) 1070 organic acids, bases, and amphoteric compounds. All data apply to dilute aqueous solutions and are presented as values of Compounds are listed by molecular formula in Hill order. pKa, which is defined as the negative of the logarithm of the equi- librium constant K for the reaction a References HA H+ + A- 1. Perrin, D. D., Dissociation Constants of Organic Bases in Aqueous i.e., Solution, Butterworths, London, 1965; Supplement, 1972. 2. Serjeant, E. P., and Dempsey, B., Ionization Constants of Organic Acids + - Ka = [H ][A ]/[HA] in Aqueous Solution, Pergamon, Oxford, 1979. 3. Albert, A., “Ionization Constants of Heterocyclic Substances”, in where [H+], etc. represent the concentrations of the respective Katritzky, A. R., Ed., Physical Methods in Heterocyclic Chemistry, - species in mol/L. It follows that pKa = pH + log[HA] – log[A ], so Academic Press, New York, 1963. 4. Sober, H.A., Ed., CRC Handbook of Biochemistry, CRC Press, Boca that a solution with 50% dissociation has pH equal to the pKa of the acid. Raton, FL, 1968. 5. Perrin, D. D., Dempsey, B., and Serjeant, E. P., pK Prediction for Data for bases are presented as pK values for the conjugate acid, a a Organic Acids and Bases, Chapman and Hall, London, 1981. i.e., for the reaction 6. Albert, A., and Serjeant, E. P., The Determination of Ionization + + Constants, Third Edition, Chapman and Hall, London, 1984. BH H + B 7. Budavari, S., Ed., The Merck Index, Twelth Edition, Merck & Co., Whitehouse Station, NJ, 1996.
    [Show full text]
  • X-Ray Fluorescence Analysis Method Röntgenfluoreszenz-Analyseverfahren Procédé D’Analyse Par Rayons X Fluorescents
    (19) & (11) EP 2 084 519 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: G01N 23/223 (2006.01) G01T 1/36 (2006.01) 01.08.2012 Bulletin 2012/31 C12Q 1/00 (2006.01) (21) Application number: 07874491.9 (86) International application number: PCT/US2007/021888 (22) Date of filing: 10.10.2007 (87) International publication number: WO 2008/127291 (23.10.2008 Gazette 2008/43) (54) X-RAY FLUORESCENCE ANALYSIS METHOD RÖNTGENFLUORESZENZ-ANALYSEVERFAHREN PROCÉDÉ D’ANALYSE PAR RAYONS X FLUORESCENTS (84) Designated Contracting States: • BURRELL, Anthony, K. AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Los Alamos, NM 87544 (US) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (74) Representative: Albrecht, Thomas Kraus & Weisert (30) Priority: 10.10.2006 US 850594 P Patent- und Rechtsanwälte Thomas-Wimmer-Ring 15 (43) Date of publication of application: 80539 München (DE) 05.08.2009 Bulletin 2009/32 (56) References cited: (60) Divisional application: JP-A- 2001 289 802 US-A1- 2003 027 129 12164870.3 US-A1- 2003 027 129 US-A1- 2004 004 183 US-A1- 2004 017 884 US-A1- 2004 017 884 (73) Proprietors: US-A1- 2004 093 526 US-A1- 2004 235 059 • Los Alamos National Security, LLC US-A1- 2004 235 059 US-A1- 2005 011 818 Los Alamos, NM 87545 (US) US-A1- 2005 011 818 US-B1- 6 329 209 • Caldera Pharmaceuticals, INC. US-B2- 6 719 147 Los Alamos, NM 87544 (US) • GOLDIN E M ET AL: "Quantitation of antibody (72) Inventors: binding to cell surface antigens by X-ray • BIRNBAUM, Eva, R.
    [Show full text]
  • Spectra Library Index Ichem/SDBS Raman Library
    Ichem / SDBS Raman スタンダードライブラリー 株式会社 エス・ティ・ジャパン S p e c t r a L i b r a r y I n d e x (Ver. 40) Ichem / SDBS Raman Library ライブラリー名:ラマンスタンダードライブラリー 商品番号:60001-40 株式会社 エス・ティ・ジャパン 〒103-0014 東京都中央区日本橋蛎殻町 1-14-10 Tel: 03-3666-2561 Fax:03-3666-2658 http://www.stjapan.co.jp 1 【販売代理店】(株)テクノサイエンス Tel:043-206-0155 Fax:043-206-0188 https://www.techno-lab-co.jp/ Ichem / SDBS Raman スタンダードライブラリー 株式会社 エス・ティ・ジャパン ((1,2-DIETHYLETHYLENE)BIS(P-PHENYLENE))DIACETATE ((2-(3-BENZYLSULFONYL-4-METHYLCYCLOHEXYL)PROPYL)SULFONYLMETHYL)BENZENE ((2,4,6-TRIOXOHEXAHYDRO-5-PYRIMIDINYL)IMINO)DIACETIC ACID ((2-CARBOXYETHYL)IMINO)DIACETIC ACID ((2-HYDROXYETHYL)IMINO)DIACETIC ACID ((2-NITROBENZYL)IMINO)DIACETIC ACID ((2-SULFOETHYL)IMINO)DIACETIC ACID ((3-(1-BROMO-1-METHYLETHYL)-7-OXO-1,3,5-CYCLOHEPTATRIEN-1-YL)OXY)DIFLUOROBORANE ((N-BENZYLOXYCARBONYL-L-ISOLEUCYL)-L-PROLYL-L-PHENYLALANYL)-N(OMEGA)-NITRO-L-ARGININE 4-NITROBENZYL ESTER (-)-2-AMINO-1-BUTANOL (-)-2-AMINO-6-MERCAPTOPURINE RIBOSIDE (-)-6,8-P-MENTHADIEN-2-OL (-)-DIACETYL-L-TARTARIC ACID (-)-DIBENZOYL-L-TARTARIC ACID (-)-DI-P-ANISOYL-L-TARTARIC ACID (-)-DI-P-TOLUOYL-L-TARTARIC ACID (-)-KAURENE (-)-MENTHOL (-)-MYRTENOL (-)-N,N,N',N'-TETRAMETHYL-D-TARTARDIAMIDE (-)-N,N'-DIBENZYL-D-TARTRAMIDE (+)-1,3,3-TRIMETHYLNORBORNANE-2-ONE (+)-2-(2,4,5,7-TETRANITRO-9-FLUORENYLIDENEAMINOOXY)PROPIONIC ACID (+)-2-AMINO-1-BUTANOL (+)-2-PINENE (+)-3,9-DIBROMOCAMPHOR (+)-3-CARENE (+)-5-BROMO-2'-DEOXYURIDINE (+)-AMMONIUM 3-BROMO-8-CAMPHORSULFONATE (+)-CAMPHOR (+)-CAMPHOR OXIME (+)-CAMPHORIC ACID (+)-CATECHIN (+)-DI-P-ANISOYL-D-TARTARIC
    [Show full text]
  • High-Value Oxy-Pharmaceuticals from P450 BM3 ‘Gatekeeper’ Mutations
    High-value oxy-pharmaceuticals from P450 BM3 ‘gatekeeper’ mutations A thesis submitted to The University of Manchester for the degree of Doctor of Philosophy in the Faculty of Science and Engineering 2018 Laura N. Jeffreys School of Chemistry BLANK PAGE 2 Table of Contents Figures……. ………………………………………………………………………………..8 Tables……………………………………………………………………………………...10 Supplementary Figures………………………………………………………………….. 11 List of Abbreviations…………………………………………………………………….. 13 Abstract…………………………………………………………………………………... 15 Acknowledgements ………………………………………………………………………16 Declaration……………………………………………………………………………….. 17 Copyright Statement…………………………………………………………………….. 18 Preface to the Journal Format Thesis………………………………………………….. 19 Author contributions……………………………………………………………………. 21 Chapter 1: General Introduction……………………………………………………... 23 1.1. An Overview of Cytochromes P450……………………………………... 23 1.1.1. The Evolution and Nomenclature of Cytochromes P450…………….23 1.1.2. The History of Cytochrome P450 Research ………………………….28 1.1.3. The P450 Catalytic Cycle …………………………………………….32 1.1.4. The Structure of P450 Enzymes ……………………………………...38 1.1.5. Unusual P450 Proteins ……………………………………………….43 1.2. The Natural Fusion Protein P450 BM3 (CYP102A1) ……………………47 1.2.1. The Structure of P450 BM3 ………………………………………….48 1.2.2. Electron Transfer Within P450 BM3 ………………………………...54 1.2.3. P450 BM3 Mutagenesis and the Gatekeeper Mutants ……………….58 1.3. Real-World Applications of P450 Enzymes ……………………………...61 1.3.1. Using P450 BM3 in the Pharmaceutical Industry ……………………63 1.3.2. Using other P450
    [Show full text]
  • Thermodynamic Investigation on As(III) and As(V) in Aqueous Solution and Extraction from Natural Water Samples by Polymer Inclusion Membranes (Pims)
    UNIVERSITÀ DEGLI STUDI DI MESSINA Dipartimento di Scienze Chimiche, Biologiche, Farmaceutiche e Ambientali DOTTORATO DI RICERCA IN SCIENZE CHIMICHE XXXII CICLO Thermodynamic investigation on As(III) and As(V) in aqueous solution and extraction from natural water samples by Polymer Inclusion Membranes (PIMs) Donatella Chillé Supervisor Prof. Claudia Foti Coordinator Prof. Paola Dugo Academic Year 2018 – 2019 This thesis was finantial supported by FSE (Fondo Sociale Europeo) regional fund. Project: Dottorati FSE XXXII Ciclo Unime CIP 2014.IT.05.SFOP.014/3/10.5/9.2.02/0006 CUP G47E16000030009 “Tenta l’incompiuto, lo straordinario Vivi in eccesso, cominciando adesso Goditi il trionfo, crea il tuo miracolo Cerca il vero amore dietro ad ogni ostacolo!” (Il mestiere della vita – Tiziano Ferro) Acknowledgements Three years could appear like an infinitely long period of time but now that I am going to write my doctoral thesis, I realize that they have passed really quickly. During this period, I had the pleasure to meet so many people who have enriched me from a professional but mainly human point and to them I address my thanks. However, there are people who deserve to be mentioned as they were pillars for me during this experience. In particular, my supervisor Prof. Claudia Foti, a very important person who, every day, guided my research activity always providing me with valuable advices. Also every single member of the analytical research group and especially Anna, Rosalia and Antonio with whome, having to share the office, I also shared “joys and sorrows”. Thank you very much for EVERYTHING. I spent part of the second year of my PhD at the University of Girona (Spain), guest of the Prof.
    [Show full text]
  • Suitability of the Use of Ph Buffers in Biological, Biochemical and Environmental Studies and Their Interaction with Metal I
    RSC Advances REVIEW (Un)suitability of the use of pH buffers in biological, biochemical and environmental studies and their Cite this: RSC Adv.,2015,5, 30989 interaction with metal ions – a review† Carlos M. H. Ferreira,a Isabel S. S. Pinto,a Eduardo V. Soaresbc and Helena M. V. M. Soares*a The use of buffers to maintain the pH within a desired range is a very common practice in chemical, biochemical and biological studies. Among them, zwitterionic N-substituted aminosulfonic acids, usually known as Good’sbuffers, although widely used, can complex metals and interact with biological systems. The present work reviews, discusses and updates the metal complexation characteristics of thirty one commercially available buffers. In addition, their impact on biological systems is also presented. The influences of these buffers on the results obtained in biological, biochemical and Received 28th November 2014 environmental studies, with special focus on their interaction with metal ions, are highlighted and Accepted 10th March 2015 critically reviewed. Using chemical speciation simulations, based on the current knowledge of the DOI: 10.1039/c4ra15453c metal–buffer stability constants, a proposal of the most adequate buffer to employ for a given metal ion www.rsc.org/advances is presented. 1. Introduction In a similar way, the pH affects enzymatic rates. This aspect is of particular importance, since during enzymatic reactions The proper maintenance of the pH is very important in several protons may be consumed or released. Thus, it is very important chemical, biochemical and biological applications. The pH to maintain the proton concentration in solution without affects the rate of chemical reactions, the efficiency of chemical interference with the enzymes.
    [Show full text]
  • Wo 2008/152444 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date PCT 18 December 2008 (18.12.2008) WO 2008/152444 A2 (51) International Patent Classification: Not classified (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (21) International Application Number: AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, PCT/IB2007/004628 CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, (22) International Filing Date: IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, 29 November 2007 (29.1 1.2007) LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, (25) Filing Language: English MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, (26) Publication Language: English TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (30) Priority Data: 60/861,620 29 November 2006 (29. 11.2006) US (84) Designated States (unless otherwise indicated, for every (71) Applicant (for all designated States except US): FOAMIX kind of regional protection available): ARIPO (BW, GH, LTD. [IL/IL]; P.O. Box 4038, 74140 Ness Ziona (IL). GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), (72) Inventors; and European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, (75) Inventors/Applicants (for US only): TAMARKIN, Dov FR, GB, GR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, PL, [IL/IL]; 537 Har Hila Street, 71908 Maccabim (IL).
    [Show full text]
  • Avra Price List 2021-22
    Avra Price List 2021-22 Catalog No CAS chemical_name HS Code Pack1 Price 1 Pack2 Price 2 Pack3 Price 3 Pack4 Price 4 ASA1001 105-57-7 Acetaldehyde diethyl acetal, 97% 29110050 25 ml 461 100 ml 1435 ASA1002 534-15-6 Acetaldehyde dimethyl acetal, 90% 29110050 25 gm 2050 100 gm 5125 500 gm 7688 ASA1003 60-35-5 Acetamide, 98% 29241980 100 gm 205 500 gm 733 ASA1005 103-84-4 Acetanilide, 95% 29242910 100 gm 236 500 gm 892 ASA1007 506-96-7 Acetyl bromide, 98% 29159050 100 ml 1128 500 ml 5330 ASA1008 517-23-7 alpha-Acetyl-gamma-butyrolactone, 98% 29322950 100 gm 2255 500 gm 7380 ASA1009 75-36-5 Acetyl chloride, 98% 29159050 500 ml 513 2.5 Lt 2255 ASA1011 67914-60-7 1-Acetyl-4-(4-hydroxyphenyl)piperazine, 98% 29335970 5 gm 923 25 gm 1845 100 gm 5638 ASA1013 93-08-3 2-Acetylnaphthalene, 99% 29143990 5 gm 369 100 gm 1199 500 gm 5023 ASA1014 32161-06-1 1-Acetyl-4-piperidone, 95% 29333961 5 ml 2000 25 ml 8200 ASA1017 1122-62-9 2-Acetylpyridine, 98% 29333991 25 gm 1538 100 gm 3588 ASA1018 350-03-8 3-Acetylpyridine, 98% 29333991 25 gm 1179 100 gm 2563 ASA1019 1122-54-9 4-Acetylpyridine, 98% 29333991 5 gm 920 25 gm 2500 100 gm 4700 ASA1020 88-15-3 2-Acetylthiophene, 95% 29349990 25 gm 950 100 gm 1900 500 gm 8500 ASA1021 1468-83-3 3-Acetylthiophene, 98% 29349990 5 gm 4100 25 gm 16000 100 gm 50000 ASA1022 4066-41-5 5-Acetyl-thiophene-2-carboxylic acid, 98% 29163975 5 gm 4900 ASA1024 79-06-1 Acrylamide, 98% 29241910 25 gm 123 100 gm 308 500 gm 769 5 Kg 4305 ASA1025 73-24-5 Adenine, 99% 29335980 5 gm 300 25 gm 1100 100 gm 2600 ASA1026 124-04-9 Adipic acid,
    [Show full text]
  • Dissociation Constants of Organic Acids and Bases ⇌ + - This Table Lists the Dissociation (Ionization) Constants of Over BH + OH
    DIssOCIATION CONSTANTS OF ORGANIC ACIDS AND BASES ⇌ + - This table lists the dissociation (ionization) constants of over BH + OH . This is related to Ka by 1070 organic acids, bases, and amphoteric compounds . All data apply to dilute aqueous solutions and are presented as values of pKa + pKb = pKwater = 14 .00 (at 25 °C) pK , which is defined as the negative of the logarithm of the equi- a Compounds are listed by molecular formula in Hill order . librium constant Ka for the reaction + - HA ⇌ H + A References i .e ., 1 . Perrin, D . D ., Dissociation Constants of Organic Bases in Aqueous + - Ka = [H ][A ]/[HA] Solution, Butterworths, London, 1965; Supplement, 1972 . 2 . Serjeant, E . P ., and Dempsey, B ., Ionization Constants of Organic Acids where [H+], etc . represent the concentrations of the respective in Aqueous Solution, Pergamon, Oxford, 1979 . - 3 . Albert, A ., “Ionization Constants of Heterocyclic Substances”, in species in mol/L . It follows that pKa = pH + log[HA] – log[A ], so Katritzky, A . R ., Ed ., Physical Methods in Heterocyclic Chemistry, that a solution with 50% dissociation has pH equal to the pKa of the acid . Academic Press, New York, 1963 . 4 . Sober, H .A ., Ed ., CRC Handbook of Biochemistry, CRC Press, Boca Data for bases are presented as pK values for the conjugate acid, a Raton, FL, 1968 . i .e ., for the reaction 5 . Perrin, D . D ., Dempsey, B ., and Serjeant, E . P ., pKa Prediction for + ⇌ + Organic Acids and Bases, Chapman and Hall, London, 1981 . BH H + B 6 . Albert, A ., and Serjeant, E . P ., The Determination of Ionization Constants, Third Edition, Chapman and Hall, London, 1984 .
    [Show full text]
  • Sigma Biochemical Condensed Phase
    Sigma Biochemical Condensed Phase Library Listing – 10,411 spectra This library provides a comprehensive spectral collection of the most common chemicals found in the Sigma Biochemicals and Reagents catalog. It includes an extensive combination of spectra of interest to the biochemical field. The Sigma Biochemical Condensed Phase Library contains 10,411 spectra acquired by Sigma-Aldrich Co. which were examined and processed at Thermo Fisher Scientific. These spectra represent a wide range of chemical classes of particular interest to those engaged in biochemical research or QC. The spectra include compound name, molecular formula, CAS (Chemical Abstract Service) registry number, and Sigma catalog number. Sigma Biochemical Condensed Phase Index Compound Name Index Compound Name 8951 (+)-1,2-O-Isopropylidene-sn-glycerol 4674 (+/-)-Epinephrine methyl ether .HCl 7703 (+)-10-Camphorsulfonic acid 8718 (+/-)-Homocitric acid lactone 10051 (+)-2,2,2-Trifluoro-1-(9-anthryl)ethanol 4739 (+/-)-Isoproterenol .HCl 8016 (+)-2,3-Dibenzoyl-D-tartaric acid 4738 (+/-)-Isoproterenol, hemisulfate salt 8948 (+)-2,3-O-Isopropylidene-2,3- 5031 (+/-)-Methadone .HCl dihydroxy-1,4-bis- 9267 (+/-)-Methylsuccinic acid (diphenylphosphino)but 9297 (+/-)-Miconazole, nitrate salt 6164 (+)-2-Octanol 9361 (+/-)-Nipecotic acid 9110 (+)-6-Methoxy-a-methyl-2- 9618 (+/-)-Phenylpropanolamine .HCl naphthaleneacetic acid 4923 (+/-)-Sulfinpyrazone 7271 (+)-Amethopterin 10404 (+/-)-Taxifolin 4368 (+)-Bicuculline 4469 (+/-)-Tetrahydropapaveroline .HBr 7697 (+)-Camphor 4992 (+/-)-Verapamil,
    [Show full text]
  • HPC-CHEM™ PART A.1 – Rare Chemicals & Solvents
    HPC-CHEM™ PART A.1 – Rare Chemicals & Solvents Catalog Pack Pack Pack CAS No Chemicals Name Price Price Price No Size Size Size ASA1001 105-57-7 Acetaldehyde diethyl acetal, 97% 25 ml 750 100 ml 2240 ASA1002 534-15-6 Acetaldehyde dimethyl acetal, 90% 25 gm 2250 100 gm 3640 500 gm 6300 ASA1003 60-35-5 Acetamide, 98% 100 gm 300 500 gm 854 ASA1005 103-84-4 Acetanilide, 95% 100 gm 300 500 gm 980 ASA1007 506-96-7 Acetyl bromide, 98% 100 ml 1800 500 ml 7560 ASA1008 517-23-7 alpha-Acetyl-gamma-butyrolactone, 98% 100 gm 2250 500 gm 5600 ASA1009 75-36-5 Acetyl chloride, 98% 2.5 Lt 3300 500 ml 700 ASA1011 67914-60-7 1-Acetyl-4-(4-hydroxyphenyl)piperazine, 98% 5 gm 2250 25 gm 7700 ASA1013 93-08-3 2-Acetylnaphthalene, 99% 5 gm 600 100 gm 1680 500 gm 7700 ASA1014 32161-06-1 1-Acetyl-4-piperidone, 95% 5 ml 3000 25 ml 11900 ASA1017 1122-62-9 2-Acetylpyridine, 98% 25 gm 2700 100 gm 6020 ASA1018 350-03-8 3-Acetylpyridine, 98% 25 gm 1650 100 gm 3640 ASA1019 1122-54-9 4-Acetylpyridine, 98% 5 gm 1350 25 gm 3500 100 gm 6020 ASA1020 88-15-3 2-Acetylthiophene, 95% 25 gm 1050 100 gm 2100 500 gm 8400 ASA1021 1468-83-3 3-Acetylthiophene, 98% 5 gm 6000 25 gm 21000 100 gm 67200 ASA1022 4066-41-5 5-Acetyl-thiophene-2-carboxylic acid, 98% 5 gm 6750 ASA1024 79-06-1 Acrylamide, 98% 25 gm 225 100 gm 420 500 gm 630 ASA1025 73-24-5 Adenine, 99% 5 gm 375 25 gm 1330 100 gm 3220 ASA1026 124-04-9 Adipic acid, 98% 500 gm 720 5 Kg 4760 ASA1032 107-18-6 Allyl alcohol, 98% 2.5 Lt 4500 100 ml 420 500 ml 980 ASA1033 107-11-9 Allylamine, 98% 25 ml 1350 100 ml 1960 500 ml 5600 ASA1035
    [Show full text]